RNA modification pattern‐based subtypes reveal heterogenous clinical outcomes and tumor immunity of clear cell renal cell carcinoma
Aimin Jiang(Second Military Medical University), Linhui Wang(Second Military Medical University), Peng Luo(Zhujiang Hospital), Silun Ge(Nanjing General Hospital of Nanjing Military Command), Le Qu(Nanjing General Hospital of Nanjing Military Command), Bing Liu(Harbin Medical University), Kai Dong(Second Military Medical University), Xiao Fang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhenjie Wu(Second Military Medical University), Anbang Wang(Second Military Medical University), Xinxin Gan(Second Military Medical University), Di Gu(First Affiliated Hospital of Guangzhou Medical University), Zi‐jun Xu(Jiangsu University)
Cited by 9
Related Papers
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
|Cancer Cell|2016|1.2k
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
|The Lancet Oncology|2023|336
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
|Journal of Clinical Oncology|2020|292